MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE... Read More

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII construct exhibited higher FVIII activity at similar integration rates compared to wild type FVIII construct in preclinical studies; program on track for IND filing in 2026 EMERYVILLE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Metagenomi,... Read More

Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC nominations in 2025 from wave 1 Ionis collaboration programs focusing on cardiometabolic indications Novel adenine base editor (ABE) and ultra small SMART editing platform demonstrated highly efficient and precise... Read More

EMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the abstract titled “Site-Specific Insertion of Factor VIII Gene Results in Durable Factor VIII Expression in Nonhuman Primates“ has been accepted for an oral presentation at the... Read More

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target deamination with no detectable translocations and no significant genomic composition differences ABE triplex editing had no adverse effects on cell viability, expansion, or other measures of cell health... Read More

Poster presentation highlights SMART adenine base editors (ABEs) small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing for therapeutically-relevant genome editing EMERYVILLE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients... Read More

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference: Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 PM ET... Read More

Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A... Read More

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that fit within delivery technologies constrained by cargo size may enable broad disease targeting EMERYVILLE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to... Read More

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences: Wells Fargo Healthcare Conference, Everett, Massachusetts Fireside chat on Wednesday, September 4, 2024, 11:00... Read More

Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 2024 All Wave 1 Ionis collaboration programs advancing in lead optimization, unlocking potential for multiple development candidate nominations in 2025 Achieved milestone from partner Affini-T related to Metagenomi licensed technology Well capitalized with $299.9M in cash, cash... Read More

EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that Metagenomi CEO and Founder, Brian C. Thomas, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m.... Read More

Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human primate durability data expected in 2H 2024 Presentation at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting demonstrated MGX base editing systems expanded genome targetability by 5-fold... Read More

EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base... Read More

Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive... Read More

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability demonstrated with CRISPR-associated transposase (CAST) system being developed to enable >10,000 base pair, targeted genomic integrations Ultra-small base editing systems (SMART) are the smallest nickase-based systems... Read More

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the... Read More